Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan-Feb;17(1):79-82.
doi: 10.1111/j.1524-4741.2010.01027.x. Epub 2010 Dec 6.

Satisfaction with physician recommendation for and information about genetic counseling among breast cancer patients

Susan T Vadaparampil  1 , Gwendolyn P Quinn, Ji-Hyun Lee, Teri Malo, Xiuhua Zhao, Cheryl Miree, Jennifer Brzosowicz
Affiliations

Satisfaction with physician recommendation for and information about genetic counseling among breast cancer patients

Susan T Vadaparampil et al. Breast J. 2011 Jan-Feb.

Abstract

To evaluate satisfaction with (a) the timing and strength of provider recommendation for and (b) information received prior to and during genetic counseling (GC) among breast cancer patients who attended GC before definitive surgery (BDS) or after definitive surgery (ADS). Satisfaction with provider recommendation for and information received about GC was evaluated among breast cancer patients who attended GC as part of their clinical care (n=51). There were no significant differences among breast cancer patients who attended GC BDS or ADS in satisfaction with when the physician referred them for GC, the strength of recommendation for GC, the amount of information provided about the GC, and the information received in GC. From a clinical perspective, the optimal time for attending GC may be BDS. Nevertheless, breast cancer patients appear satisfied with physician recommendation of and information related to GC, regardless of when they attend.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22:2328–35. - PubMed
    1. Metcalfe KA, Lynch HT, Ghadirian P, et al. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol. 2005;96:222–6. - PubMed
    1. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22:1055–62. - PubMed
    1. Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006;118:2281–4. - PubMed
    1. Daly M, Axilbund JE, Bryant E, et al. [accessed April 22, 2009];The NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian Clinical Practice Guideline, Version 1.2009. Available at: http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf. To view most recent and complete version of guideline, see http://www.nccn.org.

Publication types